info@mail.ucallm.com
From Innate Immune Identification to Functional Regulation — Empowering Comprehensive NK Cell and ILC Profiling with Validated Antibody Solutions
Natural killer (NK) cells and innate lymphoid cells (ILCs) represent critical components of the innate immune system that regulate immune surveillance, tissue homeostasis, inflammation, infection control, and tumor immunity. Unlike adaptive immune cells, NK cells and ILCs rapidly respond to environmental signals through cytokine secretion, cytotoxic activity, and immune-regulatory functions.
NK cells and ILCs share common lymphoid progenitor origins but exhibit distinct developmental programs, transcriptional networks, tissue localization patterns, and effector functions. Comprehensive characterization of these populations requires integrated analysis of:
Cell surface identity markers
Lineage-defining transcription factors
Cytotoxic effector molecules
Cytokine production profiles
Tissue-specific immune adaptation programs
NK cells primarily mediate immune surveillance through target-cell recognition and cytotoxic elimination, while ILC subsets regulate tissue immunity through specialized cytokine responses and inflammatory modulation.
We provide comprehensive antibody solutions for investigating NK cell and ILC biology—from immune population identification and lineage classification to functional pathway analysis and disease-associated immune remodeling.
Validated antibodies enable researchers to characterize:
NK cell and ILC lineage identity
Cytotoxic immune responses
Transcriptional regulation networks
Cytokine-producing immune populations
Tumor immune microenvironment composition
Tissue-resident innate lymphoid cell functions
researchers can decode innate immune networks and accelerate discoveries in cancer immunology, inflammation, autoimmune diseases, infectious diseases, and regenerative medicine.
NK Cell & ILC Biomarker Antibody Portfolio
——Comprehensive Solutions for Innate Immune Cell Identification, Functional Profiling, and Disease Mechanism Discovery
Precise characterization of NK cells and ILC populations requires integrated analysis of surface phenotype markers, transcription factors, and functional effector molecules.
Our antibody portfolio supports comprehensive profiling of major human and mouse NK/ILC subsets.
Research Focus | Representative Biomarkers | Research Applications |
Conventional NK Cell Identification (cNK) | CD3⁻CD56⁺, CD16 (FCGR3A), NKp46 (NCR1), NKp30, NKp44, KIR family, NKG2A, DNAM-1 | Identification of circulating NK cells and evaluation of cytotoxic immune surveillance |
NK Cell Transcriptional Regulation | T-bet, EOMES | Classification of NK lineage differentiation and functional maturation |
NK Cytotoxic Function | Perforin (PRF1), Granzyme B (GZMB), Granzyme A (GZMA), Granulysin (GNLY), IFN-γ, TNF-α | Analysis of NK-mediated target-cell killing and inflammatory responses |
Group 1 ILC (ILC1) Characterization | CD127 (IL-7Rα), CD161, CXCR3, CD49a, CD200R1 | Identification of tissue-resident inflammatory ILC1 populations |
ILC1 Transcriptional Identity | T-bet⁺, EOMES⁻, RORγt⁻ | Distinction between ILC1 and NK cell populations |
ILC1 Functional Profile | IFN-γ, TNF-α | Investigation of type 1 inflammatory immunity |
Group 2 ILC (ILC2) Characterization | CD127, CRTH2 (CD294), CD161, ST2 (IL-33R), ICOS, CD25, CD103 | Analysis of type 2 immune responses and tissue repair mechanisms |
ILC2 Transcriptional Regulation | GATA3, RORα | Identification of ILC2 lineage commitment |
ILC2 Effector Molecules | IL-4, IL-5, IL-13, Amphiregulin (AREG) | Study of allergic inflammation, fibrosis, and tissue remodeling |
Group 3 ILC (ILC3) Characterization | CD127, CD117 (c-Kit), NKp44, CD161, CCR6 | Identification of mucosal immune and lymphoid tissue inducer populations |
ILC3 Transcriptional Regulation | RORγt (RORC) | Characterization of IL-17/IL-22-producing innate immune populations |
ILC3 Functional Profile | IL-22, IL-17A/F, GM-CSF | Investigation of barrier immunity and inflammatory regulation |
Featured NK Cell & ILC Research Panels
——Comprehensive Antibody Panels for Innate Immune Profiling, Functional Discovery, and Disease-Oriented Research
NK cells and ILCs exhibit highly specialized immune functions regulated by distinct transcriptional programs and effector molecules. Our curated antibody panels enable systematic investigation of immune identity, lineage differentiation, cytotoxic activity, cytokine responses, and disease-associated immune remodeling.
n NK Cell Identification & Cytotoxic Function Panel—Profiling NK Cell Maturation, Activation, and Immune Surveillance
Key Markers
CD3 | CD56 | CD16 | NKp46 | NKG2A |
KIR | T-bet | EOMES | Perforin | Granzyme B |
n ILC1 Inflammatory Response Panel—Characterizing Tissue-Resident Type 1 Innate Lymphoid Immunity
Key Markers
CD127 | CD161 | CD49a | CD200R1 | T-bet | IFN-γ | TNF-α |
n ILC2 Type 2 Immunity & Tissue Remodeling Panel—Decoding Cytokine-Mediated Barrier Immunity and Repair Mechanisms
Key Markers
CD127 | CRTH2 | ST2 | ICOS | GATA3 |
RORα | IL-4 | IL-5 | IL-13 | AREG |
n ILC3 Barrier Immunity Panel—Investigating Mucosal Immunity and Inflammatory Regulation
Key Markers
CD127 | CD117 | NKp44 | CD161 | CCR6 |
RORγt | IL-22 | IL-17A/F | GM-CSF |
|
Why Researchers Choose Our NK Cell & ILC Antibody Solutions?
Validated Immune Targets. Comprehensive Panels. Reliable Innate Immunology Research.
Our antibody portfolio supports complete NK cell and ILC research workflows:
Research Challenge | Our Solution |
How can I identify NK cell populations? | CD56, CD16, NKp46, NKG2A, KIR antibody panels |
How can I distinguish NK cells from ILC1? | T-bet/EOMES transcription factor profiling |
How can I analyze ILC2 responses? | CRTH2, ST2, GATA3, IL-5/IL-13 markers |
How can I characterize ILC3 immunity? | CD117, NKp44, RORγt, IL-22/IL-17 markers |
How can I study tumor immune surveillance? | NK cytotoxicity and activation marker panels |
How can I improve reproducibility? | Validated antibodies optimized for FC, IF, IHC, and multiplex applications |
Key reference
1. Simona Sivori , Daniela Pende (2021). NK cells and ILCs in tumor immunotherapy.Molecular Aspects of Medicine 80 (2021) 100870.
2. Dang Nghiem Vo, Ouyang Yuan(2024).A temporal developmental map separates human NK cells from noncytotoxic ILCs through clonal and single-cell analysis. Blood Advances. 2024 Mar 17;8(11):2933–2951.
3. Irina Tsymala, Karl Kuchler. Innate lymphoid cells—Underexplored guardians of immunity. PLOS PATHOGENS.October 19, 2023.2023 Oct 19;19(10):e1011678.
4. Benjamin Krämer,Ansel P Nalin.Single-cell RNA sequencing identifies a population of human liver-type ILC1s.Cell Rep. 2023 Jan 1;42(1):111937.
5. Raki Sudan, Susan Gilfillan. Group 1 ILCs: Heterogeneity, Plasticity and Transcriptional Regulation. Immunol Rev. 2024 Apr 2;323(1):107–117.